Vascular endothelial growth factor receptor 3

Walter JW et al. (2002) Somatic mutation of vascular endothelial growth factor receptors in juvenile hemangioma.

Zhang Y et al. (2014) Activation of vascular endothelial growth factor receptor-3 in macrophages restrains TLR4-NF-κB signaling and protects against endotoxin shock.

Benedito R et al. (2012) Notch-dependent VEGFR3 upregulation allows angiogenesis without VEGF-VEGFR2 signalling.

Wang Y et al. (2010) Ephrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesis.

Tammela T et al. (2008) Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation.

Siekmann AF et al. (2007) Notch signalling limits angiogenic cell behaviour in developing zebrafish arteries.

Cursiefen C et al. (2006) Nonvascular VEGF receptor 3 expression by corneal epithelium maintains avascularity and vision.

Kim H et al. (2003) Molecular mechanisms in lymphangiogenesis: model systems and implications in human disease.

Karkkainen MJ et al. (2001) A model for gene therapy of human hereditary lymphedema.

Irrthum A et al. (2000) Congenital hereditary lymphedema caused by a mutation that inactivates VEGFR3 tyrosine kinase.

Dumont DJ et al. (1998) Cardiovascular failure in mouse embryos deficient in VEGF receptor-3.

Lee J et al. (1996) Vascular endothelial growth factor-related protein: a ligand and specific activator of the tyrosine kinase receptor Flt4.

Offori TW et al. (1993) Angiosarcoma in congenital hereditary lymphoedema (Milroy's disease)--diagnostic beacons and a review of the literature.

Kaipainen A et al. (1995) Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development.

Warrington JA et al. (1992) A radiation hybrid map of 18 growth factor, growth factor receptor, hormone receptor, or neurotransmitter receptor genes on the distal region of the long arm of chromosome 5.

Ferrell RE et al. (1998) Hereditary lymphedema: evidence for linkage and genetic heterogeneity.

Karkkainen MJ et al. (2000) Missense mutations interfere with VEGFR-3 signalling in primary lymphoedema.

Evans AL et al. (2003) Identification of eight novel VEGFR-3 mutations in families with primary congenital lymphoedema.

Spiegel R et al. (2006) Wide clinical spectrum in a family with hereditary lymphedema type I due to a novel missense mutation in VEGFR3.

Ghalamkarpour A et al. (2006) Hereditary lymphedema type I associated with VEGFR3 mutation: the first de novo case and atypical presentations.

Connell FC et al. (2009) Analysis of the coding regions of VEGFR3 and VEGFC in Milroy disease and other primary lymphoedemas.

Ghalamkarpour A et al. (2009) Recessive primary congenital lymphoedema caused by a VEGFR3 mutation.

Aprelikova O et al. (1992) FLT4, a novel class III receptor tyrosine kinase in chromosome 5q33-qter.

Galland F et al. (1992) Chromosomal localization of FLT4, a novel receptor-type tyrosine kinase gene.

Pajusola K et al. (1992) FLT4 receptor tyrosine kinase contains seven immunoglobulin-like loops and is expressed in multiple human tissues and cell lines.

Pajusola K et al. (1994) Signalling properties of FLT4, a proteolytically processed receptor tyrosine kinase related to two VEGF receptors.

NCBI article

OMIM.ORG article

Orphanet article

Wikipedia article